Atai Therapeutics Inc. has identified 3-alkylamine indole compounds acting as 5-HT2A receptor agonists and reported to be potentially useful for the treatment of anxiety, eating and neurological disorders.
Miralinc Pharma Inc. has patented new heterocyclic selective histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of type 2 Charcot-Marie-Tooth disease and chemotherapy-induced peripheral neuropathy, among others.
Humanwell Pharmaceutical US Inc. has synthesized new sigma non-opioid intracellular receptor 1 (SIGMAR1) antagonists reported to be useful for the treatment of cancer, pain, psychosis and substance abuse and dependence.
The central nervous system (CNS) in adult mammals has limited regeneration capacity, and traumatic injuries to the CNS usually lead to permanent functional impairment.
Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is a monogenic autoimmune disease caused by biallelic genetic variants in the AIRE gene, encoding autoimmune regulator protein.
Centessa Pharmaceuticals plc recently detailed the discovery and preclinical characterization of a novel potent and selective orexin OX2 receptor agonist, ORX-142.
Bayer AG and Moma Therapeutics Inc. have entered into a collaboration, under an option and exclusive license agreement, to develop and commercialize a small-molecule oncology program.
RSS
